Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer
Status:
Completed
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to:
-Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients
with advanced pancreatic cancer who stain for mesothelin expression
The secondary objectives of this study are to:
- Time to Progression (TTP) defined as time from study treatment to RECIST 1.1
progression, or death (others going off study will be censored)
- Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)